A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
Part of paid clinical trials in Fairhope, Alabama.
- Sponsor
- Colorado Prevention Center
- Study ID
- NCT06024746
- Phase
- PHASE3
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Finerenone — DRUGOral finerenone.
- Empagliflozin — DRUGOral empagliflozin.
Study Details
Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.
Key Dates
- First listed
- Sep 6, 2023
- Start date
- Jul 9, 2024
- Status verified
- Jul 2026
- Primary completion
- Nov 30, 2027
- Completion
- Nov 30, 2027
Study Design
- Enrollment
- 1,500 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Finerenone plus empagliflozin
- No Intervention: Usual careUsual care management
Primary Outcome Measure
Clinical benefit [ Time Frame: 6 months ]
Central Contacts
- Marc Bonaca(303) 860-9900
Locations (33)
Find similar trials in Fairhope, AL
By condition
By specialty
By research site
Related Studies
- Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy ProductsRecruiting · Medtronic · Birmingham, Alabama
- Identification of Genomic Predictors of Adverse Events After Cardiac SurgeryRecruiting · Brigham and Women's Hospital · Dallas, Texas
- Magnetic Resonance Elastography as a Method to Estimate Stiffness of Soft TissuesRecruiting · Arunark Kolipaka · Columbus, Ohio
- Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart FailureRecruiting · University of Florida · Gainesville, Florida